Definium Therapeutics, Inc. (NASDAQ:DFTX) Receives $30.33 Average PT from Analysts

Shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) have received an average recommendation of “Buy” from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, eight have issued a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $32.1111.

A number of analysts recently commented on DFTX shares. Canaccord Genuity Group lifted their price objective on Definium Therapeutics from $16.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Jones Trading assumed coverage on shares of Definium Therapeutics in a report on Tuesday, December 23rd. They set a “buy” rating and a $61.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Definium Therapeutics in a research report on Thursday. Chardan Capital upgraded shares of Definium Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Finally, Lifesci Capital upgraded Definium Therapeutics to a “strong-buy” rating in a report on Tuesday, October 14th.

Definium Therapeutics Trading Down 5.1%

Shares of DFTX opened at $16.51 on Tuesday. The company has a debt-to-equity ratio of 0.31, a current ratio of 3.30 and a quick ratio of 3.30. Definium Therapeutics has a 1-year low of $4.70 and a 1-year high of $18.12. The stock has a market cap of $1.63 billion, a price-to-earnings ratio of -8.09 and a beta of 2.57. The firm has a 50 day simple moving average of $13.27 and a 200-day simple moving average of $11.53.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, November 6th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.26). Equities analysts forecast that Definium Therapeutics will post -1.35 EPS for the current fiscal year.

Insider Activity at Definium Therapeutics

In other news, CEO Robert Barrow sold 25,791 shares of the company’s stock in a transaction dated Friday, December 26th. The shares were sold at an average price of $13.15, for a total transaction of $339,151.65. Following the completion of the transaction, the chief executive officer owned 778,477 shares of the company’s stock, valued at $10,236,972.55. This represents a 3.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Daniel Karlin sold 5,600 shares of the stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the transaction, the insider owned 425,025 shares in the company, valued at approximately $5,589,078.75. The trade was a 1.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 42,667 shares of company stock worth $561,071. 2.26% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of DFTX. Marshall Wace LLP raised its position in shares of Definium Therapeutics by 31.9% in the 2nd quarter. Marshall Wace LLP now owns 3,421,224 shares of the company’s stock worth $22,204,000 after buying an additional 828,067 shares during the period. Geode Capital Management LLC increased its stake in Definium Therapeutics by 4.0% during the second quarter. Geode Capital Management LLC now owns 1,733,454 shares of the company’s stock worth $11,252,000 after acquiring an additional 66,663 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Definium Therapeutics in the 2nd quarter worth about $238,000. Stempoint Capital LP acquired a new position in shares of Definium Therapeutics in the 2nd quarter valued at about $590,000. Finally, Diadema Partners LP purchased a new stake in shares of Definium Therapeutics during the 2nd quarter worth about $1,029,000. Institutional investors and hedge funds own 27.91% of the company’s stock.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.